OCX

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Retrieved on: 
Thursday, March 2, 2023
Oncocyte, Research, Business, Chairperson, Patient, Transplant, OCX, Interim, Business development, Management

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.

Key Points: 
  • IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.
  • Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization.
  • Riggs also serves as President and joins the Company’s Board of Directors.
  • “Oncocyte has differentiated technology in multiple $1B+ clinical and research markets.” said Joshua Riggs.

MOD Mission Critical Enhances Hybrid Cloud Offering by Leveraging the Open Cloud Exchange®

Retrieved on: 
Monday, February 27, 2023
Data Management, Security, Technology, Software, Networks, Internet, Cloud, Ecosystem, OCX, NYSE, SLA, Organization, Partnership, Solution architecture, Architecture, Open Cloud Computing Interface, American Tower, TCO, CoreSite, IP, Platform, MOD, Video game

CoreSite , a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”), today announced that MOD Mission Critical (MOD), an international managed services provider specializing in colocation and IP services solutions, has expanded its capabilities to address multicloud and hybrid-cloud opportunities through the Open Cloud Exchange® (OCX).

Key Points: 
  • CoreSite , a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”), today announced that MOD Mission Critical (MOD), an international managed services provider specializing in colocation and IP services solutions, has expanded its capabilities to address multicloud and hybrid-cloud opportunities through the Open Cloud Exchange® (OCX).
  • MOD’s PaaSPort™ platform provides customers with an easy-to-use interface to order multicloud, hybrid-cloud and private-cloud connectivity solutions, along with a full suite of services specifically designed to enable multi-facility, multicloud (hybrid) and multi-network solution deployments world-wide.
  • MOD recently integrated into the OCX, a leading software-defined interconnection platform, to seamlessly deliver cloud connectivity solutions to its customer base.
  • “This relationship is a perfect example of how the Open Cloud Exchange® can support organizations and managed service providers to increase their competitive edge and win in the marketplace.”

Oncocyte Completes Razor Genomics Transaction

Retrieved on: 
Wednesday, February 22, 2023
OCX, Sale, Genomics, Oncocyte, Patient, Cryptocurrency, Sales, Bank

IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific. The deal eliminates an estimated $8M of annual operating expense and $13M of future milestone and development obligations, while allowing Razor Genomics to maintain continuity of service for DetermaRxTM patients and clinicians. Oncocyte retains a 30% equity stake. The transaction involved the transfer of all the assets and liabilities related to DetermaRx.  

Key Points: 
  • IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific.
  • The deal eliminates an estimated $8M of annual operating expense and $13M of future milestone and development obligations, while allowing Razor Genomics to maintain continuity of service for DetermaRxTM patients and clinicians.
  • “We believe that this transaction preserves upside opportunity for Oncocyte shareholders while eliminating nearly $30M of estimated operating expense, future milestone and development obligations in the aggregate over the next two years.
  • Oncocyte is well positioned to achieve 2023 commercial and developmental milestones in its key product lines.”

Oncocyte Announces Initiatives to Focus Corporate Strategy

Retrieved on: 
Friday, December 16, 2022
Physician, Diagnosis, Intellectual property, Tumor microenvironment, OCX, Failure, Neoplasm, Accounting, Lung cancer, Cancer, Maintenance, Recurrence, Certification, Risk, COVID-19, Patient, Risk management, Pharmaceutical industry, Razor

The transaction involves the transfer of all of the assets and liabilities related to DetermaRx.

Key Points: 
  • The transaction involves the transfer of all of the assets and liabilities related to DetermaRx.
  • The closing of the transaction will occur at a later date, subject to the satisfaction of the closing conditions set forth in the agreement.
  • Oncocyte expects that Ms. Paulsen and Dr. Ross will serve as advisors during a transition phase over the next quarter.
  • Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Diagnosis, Certification, American studies, Physician, MBA, Patient, West Pharmaceutical Services explosion, Neoplasm, Tumor microenvironment, Telehealth, Maintenance, Accounting, Cancer, Harvard Business School, OCX, Amherst College, Intellectual property, Failure, Pharmaceutical industry, Management, Medicine

I am pleased to announce the appointment of Lou as a member of our Board, said Andy Arno, Chair of Oncocytes Board of Directors.

Key Points: 
  • I am pleased to announce the appointment of Lou as a member of our Board, said Andy Arno, Chair of Oncocytes Board of Directors.
  • Mr. Silverman serves as a board member at a venture backed health care-oriented fin-tech company and a hospital system based in the Northeast.
  • Mr. Silverman earned his BA in American Studies (cum laude) from Amherst College and his MBA from Harvard Business School.
  • I am honored to be joining the Oncocyte Board of Directors," said Mr. Silverman.

Oncocyte Announces Executive Leadership Changes

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Diagnosis, Certification, Transplant, Physician, Patient, West Pharmaceutical Services explosion, Neoplasm, Tumor microenvironment, Maintenance, Accounting, Cancer, OCX, Research, Intellectual property, Failure, Management, Pharmaceutical industry, Oncocyte

I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.

Key Points: 
  • I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.
  • On behalf of the Board, I want to wish Ronnie all the best in his future endeavors and to thank him for his many contributions to Oncocyte, including his leadership and mentorship of Josh, said Andy Arno, Chairman of the Board.
  • The Board intends to begin a search for a permanent Chief Executive Officer shortly, and expects that Josh will be a candidate.
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Oncocyte to Announce Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, October 27, 2022
Telephone, Cancer, OCX, Company, Physician, Neoplasm, Interest, Patient, Tumor microenvironment, GLOBE, Diagnosis, Nasdaq, Pharmaceutical Services Negotiating Committee, Pharmaceutical industry

IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022.

Key Points: 
  • IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022.
  • In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
  • DetermaRx, DetermaIO, DetermaTx, DetermaCNI, DetermaMx and VitaGraft are trademarks of Oncocyte Corporation.

DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer

Retrieved on: 
Thursday, October 6, 2022
Physician, U.S. Securities and Exchange Commission, Lymph, Pembrolizumab, Observation, SEC, Quality, Neoplasm, Diagnosis, SWOG, Patient, Research, Tissue, Nasdaq, History, Cancer, Technology, Certification, Goal, Tumor microenvironment, Company, National Cancer Institute, MD, TNBC, OCX, Breast cancer, West Pharmaceutical Services explosion, National, GLOBE, Accounting, Clinical trial, Maintenance, Intellectual property, Forward-looking statement, Failure, COVID-19, NCI, Medical imaging, Pharmaceutical industry, Oncocyte

These tissues were collected during the S1418 Phase III randomized clinical trial of Keytruda (pembrolizumab) in primary triple negative breast cancer (TNBC).

Key Points: 
  • These tissues were collected during the S1418 Phase III randomized clinical trial of Keytruda (pembrolizumab) in primary triple negative breast cancer (TNBC).
  • We are excited to partner with Oncocyte to test DetermaIO in the S1418 trial, said Lajos Pusztai, MD, principal investigator.
  • DetermaIO was selected by SWOG as part of a grant proposal to the NCI's Biomarker, Imaging, and Quality of Life Studies Funding Program.
  • To be partnered with SWOG, in a prospectively designed biomarker study in a large, randomized clinical trial, marks a major milestone for DetermaIO.

CoreSite Launches New Interconnection Product to Increase High-Speed Bandwidth Options for Customers

Retrieved on: 
Tuesday, October 4, 2022
Technology, Mobile, Wireless, 5G, Telecommunications, Software, Networks, Internet, Hardware, Data Management, Cloud, Solution, Internet, VP, CoreSite, Alibaba Cloud, Ownership, Ecosystem, LINX, OCX, TCO, DE-CIX, NYSE, Microsoft, Data-rate units, IP, Efficiency, Cross, AMS-IX, American Tower, Google Cloud Platform, IBM, Rocky Mountains, Renewable energy, Internet service provider

CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (American Tower), today announced the release of 100G bandwidth availability for the companys metro inter-site product .

Key Points: 
  • CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (American Tower), today announced the release of 100G bandwidth availability for the companys metro inter-site product .
  • This expanded solution in CoreSites interconnection portfolio enables businesses to integrate and securely scale their critical IT infrastructure by connecting network, applications and data in the same market.
  • The new metro inter-site ethernet product enables customers to have high-speed bandwidth options required for connectivity in the same market including one Gbps, 10 Gbps and 100 Gbps.
  • Additionally, the company partners with top internet exchanges, including AMS-IX, DE-CIX, LINX, NYIIX, United IX and BBIX, offering customers interconnection and peering options natively within CoreSites data center locations.

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS

Retrieved on: 
Wednesday, September 7, 2022
TNM, Lung cancer, Neoplasm, COVID-19, Technology, Cancer, LCD, Tumor microenvironment, Recurrence, Maintenance, CMS, Public opinion, Scientific and Technical Advisory Panel, National, Â, Physician, Diagnosis, SEC, U.S. Securities and Exchange Commission, OCX, Goal, Accounting, GLOBE, West Pharmaceutical Services explosion, CPT, Nasdaq, Company, Immunotherapy, Certification, NSCLC, Failure, Risk, Intellectual property, Forward-looking statement, Patient, Pharmaceutical industry, Medicare

Medicare (CMS) will consider this recommendation and is expected to post its preliminary decision in mid-September for public comments and issue a final determination in mid-November.

Key Points: 
  • Medicare (CMS) will consider this recommendation and is expected to post its preliminary decision in mid-September for public comments and issue a final determination in mid-November.
  • We were also encouraged by the recommendation by CMSs advisory panel to move DetermaRx into a high-value category and await the posting of the final decision.
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.